Urogen Pharma (NASDAQ:URGN) Stock Has Average Price Target of $52.38 According to Brokerages

Urogen Pharma (NASDAQ:URGN) has earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $52.38.

A number of research analysts recently issued reports on the stock. TD Cowen lifted their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Guggenheim boosted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $56.00 target price on shares of Urogen Pharma in a report on Thursday, September 10th.

Urogen Pharma Stock Down 4.4%

URGN stock opened at $36.58 on Monday. The company has a market cap of $1.79 billion, a PE ratio of -18.47 and a beta of 1.57. The business has a 50-day simple moving average of $43.58 and a 200 day simple moving average of $35.13. Urogen Pharma has a 52 week low of $16.36 and a 52 week high of $50.81.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. On average, analysts anticipate that Urogen Pharma will post -0.20 EPS for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. This trade represents a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Chris Degnan sold 2,202 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the sale, the chief financial officer directly owned 4,561 shares in the company, valued at $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 65,269 shares of company stock valued at $3,037,646. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Partners Capital Investment Group LLP bought a new position in Urogen Pharma in the 2nd quarter valued at approximately $566,000. Legal & General Group Plc acquired a new stake in Urogen Pharma in the second quarter valued at approximately $1,319,000. California State Teachers Retirement System boosted its position in Urogen Pharma by 1,605.5% in the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after buying an additional 36,478 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of Urogen Pharma during the second quarter worth $11,064,000. Finally, Deutsche Bank AG bought a new stake in shares of Urogen Pharma during the second quarter worth $1,897,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.